Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 11/20 | 0.60 |
| ▸ | GRM5 | P41594 | 11/20 | 0.60 |
| ▸ | CDK9 | P50750 | 4/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29766150 | 0.89 | GRM1 (0.50) | GRM1GRM5CDK9CCNT1PDK4 | |
| SCHEMBL20760680 | 0.89 | GRM1 (0.50) | GRM1GRM5CDK9CCNT1PDK4 | |
| SCHEMBL20760645 | 0.88 | MAPT (0.52) | GRM1GRM5PDK4NAMPT | |
| SCHEMBL15756312 | 0.88 | GRM1 (0.59) | GRM1GRM5CDK9CCNT1PDK4 | |
| SCHEMBL20759621 | 0.87 | GRM1 (0.53) | GRM1GRM5CDK9CCNT1PDK4 | |
| SCHEMBL29766107 | 0.86 | GRM1 (0.48) | GRM1GRM5CDK9CCNT1PDK4 | |
| SCHEMBL20760865 | 0.86 | GRM1 (0.48) | GRM1GRM5CDK9CCNT1PDK4 | |
| SCHEMBL64701 | 0.83 | GRM1 (0.55) | GRM1GRM5PDK4NAMPT | |
| SCHEMBL28368651 | 0.83 | NPC1 (0.44) | GRM1GRM5NAMPT | |
| SCHEMBL15756310 | 0.83 | GRM1 (0.55) | GRM1GRM5PDK4NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240010652-A1 | COMPOSITIONS AND METHODS FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | BLUEPRINT MEDICINES CORPORATION | 2024-01-11 | — | — | US | disclosed |
| CN-117098760-A | Compositions and methods for treating KIT and PDGFRA mediated diseases | 缆图药品公司 | 2023-11-21 | — | — | CN | disclosed |
| EP-4229060-A1 | COMPOSITIONS AND METHODS FOR TREATING KIT-AND PDGFRA-MEDIATED DISEASES | Blueprint Medicines Corporation (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-110891953-B | Pyrrolotriazines derivatives, preparation method and application thereof | 浙江海正药业股份有限公司 | 2022-07-12 | — | — | CN | disclosed |
| WO-2022081627-A1 | COMPOSITIONS AND METHODS FOR TREATING KIT-AND PDGFRA-MEDIATED DISEASES | BLUEPRINT MEDICINES CORPORATION (US) | 2022-04-21 | — | — | WO | disclosed |
| CN-110891953-A | Pyrrolotriazines derivatives, preparation method and application thereof | 浙江海正药业股份有限公司 | 2020-03-17 | — | — | CN | disclosed |
| WO-2019034128-A1 | PYRROLOTRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | 浙江海正药业股份有限公司 | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240010652-A1 | COMPOSITIONS AND METHODS FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | KIT, PDGFRA, PDGFRB | GRM1 1271/4885GRM5 1548/4885CDK9 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.